iShares Core MSCI China Index ETF(02801.HK) fell 1.45% to HKD 25.820
Newtimespace News, as of 13:12 on May 8, iShares Core MSCI China Index ETF(02801.HK) was quoted at HKD 25.820, down 1.45%. The ETF opened at HKD 25.900, with a high of HKD 25.960 and a low of HKD 25.820. The latest NAV per unit is HKD 26.136, with a premium rate of 0.25%. The asset size is approximately HKD 16.23 billion.
iShares Core MSCI China Index ETF(02801.HK) aims to track the performance of the MSCI China Index. The index covers large and mid-cap Chinese company stocks listed in Mainland China, Hong Kong, and overseas (such as the United States). Its constituents span multiple core sectors including finance, information technology, consumer goods, and communication services, making it one of the key international benchmarks for measuring the overall performance of China concept stocks.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment